Anaplastic thyroid cancer

Rohit Ranganath, Manish A. Shah, Ashok R. Shah

Research output: Contribution to journalReview articlepeer-review


Purpose of review Anaplastic thyroid cancer (ATC) is a rare malignancy of the thyroid with a high mortality rate. Conventional therapy has not been effective. Several biological agents are being investigated. The purpose of the review is to highlight the current standards for treatment and review new targets for treating ATC. Recent findings Retrospective studies have led to formulation of guidelines for management, including those by the American Thyroid Association. An expansion in the understanding of the genetic mutations has led to several newer biological agents being tested to treat ATC. Aurora kinase inhibitors, PPAR γ agonists, and vascular targeting agents are some of the latest therapeutic agents that have shown promise and could become standard of therapy with further supporting research. Summary Further well coordinated preclinical and clinical research is needed to support the emerging treatments for ATC.

Original languageEnglish (US)
Pages (from-to)387-391
Number of pages5
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Issue number5
StatePublished - Jan 1 2015


  • anaplastic
  • anaplastic thyroid cancer
  • cancer
  • novel therapies
  • thyroid

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics


Dive into the research topics of 'Anaplastic thyroid cancer'. Together they form a unique fingerprint.

Cite this